Donate For Public and Patients Store Search

U061 - Clinical Trials in Dermatology

Sunday, March 3; 7:00 AM - 8:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss the role of clinical trials in dermatology.
  • Formulate strategies for incorporating clinical trials into a dermatology practice.
  • Recognize the benefits and drawbacks of conducting clinical trials in dermatology.

Description

In dermatology, there has been a dramatic growth in the need for clinical research. Biotechnology has generated a multitude of potential candidates for future therapies, but a bottleneck--clinical trials--is a rate limiting step in progress between the bench and the bedside. Well conducted clinical trials are a critical component of the approval process for new therapies, and require investigators, yet clinical investigators for dermatology trials are in short supply. This session describes the process of conducting dermatology clinical trials, along with benefits, such as development of a niche; enhancing clinical and scientific skills; offering patients novel treatments; and contributing to the fund of medical knowledge.

Disclosures

  • Bhatia, Neal D., MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); BMS – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dr. Reddy – A(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Naked Biome, Inc. – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Vidac Pharma – I(Grants/Research Funding); Vyome Therapeutics Limited – C(Grants/Research Funding);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Nasir, Adnan, MD, PhD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Allergan, Inc – I(Grants/Research Funding); Amgen – I(OB); Biorasi, LLC – I(Grants/Research Funding); BMS – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Demira – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Escalier Biosciences – I(Grants/Research Funding); Foamix – I(Grants/Research Funding); Gage Development Company, LLC – I(Grants/Research Funding); Galderma Research & Development, LLC – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); PPD Inc. – I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Trevi Therapeutics – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Schlesinger, Todd, MD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding); Allergan, Inc – C(H), I(Grants/Research Funding); Almirall – A(H), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding); Bioderma – A(H); Biofrontera – I(Grants/Research Funding); Biofrontera AG – A(H); Boehringer Ingelheim – I(Grants/Research Funding); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Coherus Biosciences – I(Grants/Research Funding); Corrona, Inc. – I(Grants/Research Funding); Demira – I(Grants/Research Funding), SP(H); Dermavant Sciences – I(Grants/Research Funding); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); Greenway Therapeutix – A(NC); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Merz Aesthetics – C(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Regeneron – C(Fees), I(Grants/Research Funding), SP(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Remedly, Inc – A(SO); Sanofi Genzyme – SP(H); Sebacia, Inc. – I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); SiSaf, Ltd. – Independent Contractor(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – SP(H); Suneva Medical, Inc. – A(H), Speaker/Faculty Education(H); Unilever – C(H);
Schedule
Sunday, March 3
7:30 AM
All faculty / Clinical Trials in Dermatology
Event Details
  • Date
    Sunday, March 3
  • Time
    7:00 AM - 8:00 AM
  • Location
    Room 154A
  • CME Credits
    1.00
  • Type
    New
Directors/Co-Directors
  • Adnan Nasir, MD, PhD, FAAD
Speakers
  • Emma Guttman, MD, PhD, FAAD - Handout
  • Neal D. Bhatia, MD, FAAD - Handout
  • Todd Schlesinger, MD, FAAD